265 related articles for article (PubMed ID: 19703345)
1. The role of an alginate suspension on pepsin and bile acids - key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease?
Strugala V; Avis J; Jolliffe IG; Johnstone LM; Dettmar PW
J Pharm Pharmacol; 2009 Aug; 61(8):1021-8. PubMed ID: 19703345
[TBL] [Abstract][Full Text] [Related]
2. Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease.
Tack J
Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 2():10-6. PubMed ID: 16939428
[TBL] [Abstract][Full Text] [Related]
3. Bioadhesive oesophageal bandages: protection against acid and pepsin injury.
Tang M; Dettmar P; Batchelor H
Int J Pharm; 2005 Mar; 292(1-2):169-77. PubMed ID: 15725563
[TBL] [Abstract][Full Text] [Related]
4. Review article: role of pepsin and bile in gastro-oesophageal reflux disease.
Tack J
Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():48-54. PubMed ID: 16042659
[TBL] [Abstract][Full Text] [Related]
5. Bile acids in laryngopharyngeal refluxate: will they enhance or attenuate the action of pepsin?
Ali MS; Parikh S; Chater P; Pearson JP
Laryngoscope; 2013 Feb; 123(2):434-9. PubMed ID: 23070961
[TBL] [Abstract][Full Text] [Related]
6. Circadian variations in gastric acid and pepsin secretion and intragastric bile acid in patients with reflux esophagitis and in healthy controls.
Fiorucci S; Distrutti E; Di Matteo F; Brunori P; Santucci L; Mallozzi E; Bigazzi U; Morelli A
Am J Gastroenterol; 1995 Feb; 90(2):270-6. PubMed ID: 7847299
[TBL] [Abstract][Full Text] [Related]
7. Raft-forming agents: antireflux formulations.
Kapadia CJ; Mane VB
Drug Dev Ind Pharm; 2007 Dec; 33(12):1350-61. PubMed ID: 18097809
[TBL] [Abstract][Full Text] [Related]
8. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease.
Rohof WO; Bennink RJ; Smout AJ; Thomas E; Boeckxstaens GE
Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1585-91; quiz e90. PubMed ID: 23669304
[TBL] [Abstract][Full Text] [Related]
9. Review article: the nature of oesophageal injury in gastro-oesophageal reflux disease.
De Hertogh G; Ectors N; Van Eyken P; Geboes K
Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 2():17-26. PubMed ID: 16939429
[TBL] [Abstract][Full Text] [Related]
10. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes.
Dettmar PW; Sykes J; Little SL; Bryan J
Int J Clin Pract; 2006 Mar; 60(3):275-83. PubMed ID: 16494641
[TBL] [Abstract][Full Text] [Related]
11. Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin.
Chater PI; Wilcox MD; Brownlee IA; Pearson JP
Carbohydr Polym; 2015 Oct; 131():142-51. PubMed ID: 26256170
[TBL] [Abstract][Full Text] [Related]
12. The role of gastric and duodenal agents in laryngeal injury: an experimental canine model.
Adhami T; Goldblum JR; Richter JE; Vaezi MF
Am J Gastroenterol; 2004 Nov; 99(11):2098-106. PubMed ID: 15554987
[TBL] [Abstract][Full Text] [Related]
13. A comparative study on the raft chemical properties of various alginate antacid raft-forming products.
Dettmar PW; Gil-Gonzalez D; Fisher J; Flint L; Rainforth D; Moreno-Herrera A; Potts M
Drug Dev Ind Pharm; 2018 Jan; 44(1):30-39. PubMed ID: 28836872
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of pepsin activity by alginates in vitro and the effect of epimerization.
Strugala V; Kennington EJ; Campbell RJ; Skjåk-Braek G; Dettmar PW
Int J Pharm; 2005 Nov; 304(1-2):40-50. PubMed ID: 16139974
[TBL] [Abstract][Full Text] [Related]
15. The refluxate: The impact of its magnitude, composition and distribution.
Woodland P; Sifrim D
Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):861-71. PubMed ID: 21126699
[TBL] [Abstract][Full Text] [Related]
16. Composition of gastro-oesophageal refluxate.
Gotley DC; Morgan AP; Ball D; Owen RW; Cooper MJ
Gut; 1991 Oct; 32(10):1093-9. PubMed ID: 1955160
[TBL] [Abstract][Full Text] [Related]
17. Review article: human pepsins - their multiplicity, function and role in reflux disease.
Roberts NB
Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 2():2-9. PubMed ID: 16939427
[TBL] [Abstract][Full Text] [Related]
18. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces.
Farré R; van Malenstein H; De Vos R; Geboes K; Depoortere I; Vanden Berghe P; Fornari F; Blondeau K; Mertens V; Tack J; Sifrim D
Gut; 2008 Oct; 57(10):1366-74. PubMed ID: 18593808
[TBL] [Abstract][Full Text] [Related]
19. Bronchoalveolar pepsin, bile acids, oxidation, and inflammation in children with gastroesophageal reflux disease.
Starosta V; Kitz R; Hartl D; Marcos V; Reinhardt D; Griese M
Chest; 2007 Nov; 132(5):1557-64. PubMed ID: 17925430
[TBL] [Abstract][Full Text] [Related]
20. Alginate-antacid combinations: raft formation and gastric retention studies.
Hampson FC; Jolliffe IG; Bakhtyari A; Taylor G; Sykes J; Johnstone LM; Dettmar PW
Drug Dev Ind Pharm; 2010 May; 36(5):614-23. PubMed ID: 19925256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
